The Neuroscience of Being Human

The Neuroscience of Amphetamines

How transporter reversal floods the synapse with dopamine and norepinephrine, why the same molecule treats ADHD and destroys brains depending on dose, and what neuroimaging reveals about stimulant dependence, psychosis, and structural recovery

1,560-word article with 8 Harvard references.

Transporter reversal: how amphetamine floods the synapse

Cocaine blocks the dopamine transporter from the outside. Amphetamine does something more aggressive: it enters through the transporter, gets inside the presynaptic terminal, and then forces the transporter to run in reverse. Sulzer et al. (2005), in the most comprehensive review of amphetamine's mechanism, described a three-step process. First, amphetamine is a substrate for the dopamine transporter, meaning DAT recognises it as cargo and transports it into the cell. Second, once inside, amphetamine inhibits vesicular monoamine transporter 2 (VMAT2), the protein that packages dopamine into synaptic vesicles for regulated release. Dopamine leaks from vesicles into the cytoplasm. Third, the accumulation of cytoplasmic dopamine, combined with amphetamine's direct effects on DAT conformation, causes the transporter to reverse direction, pumping dopamine out of the cell and into the synaptic cleft through the same channel it normally uses to bring dopamine in.

The same mechanism operates at the norepinephrine transporter, producing parallel efflux of norepinephrine. Calipari and Ferris (2013) refined this model by demonstrating that amphetamine also increases the number of DAT molecules at the cell surface, amplifying the reverse-transport effect. The net result is a synaptic dopamine concentration far exceeding anything produced by normal neural activity and exceeding what cocaine achieves through blockade alone. Amphetamine does not merely prevent dopamine from being cleared. It actively pumps it out. The subjective experience at recreational doses is intense euphoria, increased energy, heightened confidence, and a sense of cognitive clarity that, at therapeutic doses, translates into improved sustained attention and executive function.

The ADHD brain: why a stimulant calms

The paradox that a powerful stimulant improves attention and reduces hyperactivity in ADHD has a neurobiological explanation. Volkow et al. (2009), using PET imaging, found that individuals with ADHD have significantly elevated dopamine transporter density in the striatum compared to neurotypical controls. More transporters means faster clearance of dopamine from the synapse. The dopaminergic signal that should sustain attention, reinforce goal-directed behaviour, and support executive function is terminated prematurely. The brain compensates by seeking stimulation, producing the restlessness, distractibility, and reward-seeking behaviour that characterise the disorder.

Therapeutic doses of amphetamine, typically five to thirty milligrams of mixed amphetamine salts per day, compensate for this excessive transporter activity by reversing a proportion of the surplus transporters and maintaining dopamine in the synaptic cleft for the duration that neurotypical signalling would provide. The effect is not stimulation in the recreational sense. It is normalisation. The ADHD brain with appropriate amphetamine dosing functions more like a neurotypical brain, not like a neurotypical brain on stimulants. The Cochrane review by Castells et al. (2011) confirmed the efficacy of amphetamines for adult ADHD, with significant improvements in ADHD symptom severity, response rates, and clinician-rated global improvement across randomised controlled trials. The therapeutic margin, however, is narrow. The difference between a dose that normalises prefrontal dopamine and a dose that overwhelms mesolimbic dopamine is measured in milligrams.

Methamphetamine: when the molecule becomes neurotoxic

Methamphetamine shares amphetamine's basic mechanism but adds features that make it substantially more neurotoxic. Cruickshank and Dyer (2009), reviewing the clinical pharmacology, documented the key differences. Methamphetamine is more lipophilic than d-amphetamine, crosses the blood-brain barrier more rapidly, and achieves higher brain concentrations. It releases serotonin as well as dopamine and norepinephrine, broadening its monoamine disruption. Most critically, its metabolism produces reactive oxygen species and hydroxyl radicals that damage neuronal membranes, mitochondria, and axon terminals through oxidative stress.

The consequence is terminal degeneration. The axon terminals of dopaminergic neurons in the striatum and serotonergic neurons throughout the cortex are physically damaged, not merely depleted. PET imaging of chronic methamphetamine users shows reduced dopamine transporter density and reduced serotonin transporter density that persists for months after cessation. The clinical correlates are anhedonia, cognitive slowing, impaired executive function, and emotional dysregulation that outlast the acute withdrawal period. Some recovery of transporter density occurs with prolonged abstinence, but the timeline is measured in months to years and the extent of recovery is variable. D-amphetamine at therapeutic doses does not produce this terminal degeneration because the doses are orders of magnitude lower and the oxidative stress mechanisms are not significantly activated.

Amphetamine psychosis: when dopamine becomes delusion

At sufficiently high doses, or after prolonged binge use without sleep, amphetamines produce a psychotic state that is clinically indistinguishable from acute paranoid schizophrenia. Bramness et al. (2012) reviewed the phenomenon and the diagnostic challenge it presents. Amphetamine psychosis typically manifests as paranoid delusions, often persecutory in nature, accompanied by auditory hallucinations, ideas of reference, and agitation. The patient is convinced they are being followed, monitored, or threatened. The perceptual distortions are vivid and internally consistent. Without a drug history, the presentation is indistinguishable from a first episode of primary psychosis.

The mechanism is dopaminergic. Excessive dopamine activity in the mesolimbic pathway, particularly in the ventral striatum and the associative striatum, produces aberrant salience assignment. Stimuli that should be ignored are tagged as significant. Coincidences are interpreted as meaningful. The brain's pattern-detection machinery, running in a hyperdopaminergic state, finds patterns and threats where none exist. The finding contributed significantly to the dopamine hypothesis of schizophrenia, the proposal that psychotic symptoms in schizophrenia arise from dysregulated dopamine signalling in the same pathways that amphetamine overstimulates. Amphetamine psychosis typically resolves within days to weeks of cessation, assisted by dopamine antagonist medication, but a subset of individuals, particularly those with pre-existing vulnerability, develop persistent psychotic symptoms that outlast the acute intoxication.

Structural brain damage: what the meta-analysis reveals

Ersche et al. (2013) conducted a meta-analysis of structural neuroimaging studies in individuals dependent on stimulants, including amphetamine and methamphetamine. The findings documented consistent patterns of grey matter reduction across studies. The prefrontal cortex, the region responsible for impulse control, consequence evaluation, and executive decision-making, showed the most consistent volume reductions. The insula, involved in interoception and emotional awareness, was also consistently affected. Temporal lobe structures, including regions involved in memory and emotional processing, showed significant grey matter loss.

The magnitude of structural change correlated with the duration and severity of stimulant use, consistent with a dose-dependent neurotoxic process rather than a pre-existing vulnerability. The prefrontal atrophy is particularly consequential because it creates a neurobiological feedback loop: the region responsible for inhibiting drug-seeking behaviour is the region most damaged by the drug. The person's capacity to resist the impulse to use is progressively degraded by the very behaviour it needs to resist. This is not a metaphor for loss of willpower. It is a measurable structural deficit in the neural tissue that implements volitional control.